Reduction of direct and indirect costs in patients with AS receiving etanercept: Results from an open-label 36-week extension of the ascend study in four european countries

Rheumatology

Volumn 51, Issue 2, 2012, Pages 393-396

  Moots, Robert J ^a   Ostor, Andrew J K ^b   Loft, Anne G R ^c   Järvinen, Pentti ^d   Larsson, Per ^e   Ekelund, Mats ^f   Reynolds, Alan ^g,i   Kielar, Danuta ^f,j   Lindkvist, Rose Marie ^h   Qvitzau, Susanne ^g  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c LILLEBAELT HOSPITAL   (Denmark)

^d Kiljava Medical Research   (Finland)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f PFIZER INC   (United States)

^g PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^h Pfizer Europe   (United Kingdom)

ⁱ Reynolds Clinical Sciences Ltd   (United Kingdom)

^j UCB PHARMA   (Belgium)

more..

Author keywords

Ankylosing spondylitis; Biologic therapy; Cost analysis; Health economics

Indexed keywords

ETANERCEPT;

ABSENTEEISM; ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTICLE; CONTROLLED STUDY; COST OF ILLNESS; CROHN DISEASE; DEMYELINATING DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; EUROPE; FEMALE; HEALTH CARE COST; HODGKIN DISEASE; HOSPITAL PATIENT; HUMAN; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL LEAVE; MULTICENTER STUDY; OUTPATIENT; PATIENT CARE; PHASE 4 CLINICAL TRIAL; PHYSIOTHERAPIST; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SPINE FRACTURE; TREATMENT DURATION; TUBERCULOSIS; ULCERATIVE COLITIS; WORK CAPACITY;

ADULT; AGED; ANTIRHEUMATIC AGENTS; EFFICIENCY; EMPLOYMENT; FEMALE; HEALTH CARE COSTS; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; QUALITY OF LIFE; RECEPTORS, TUMOR NECROSIS FACTOR; SICK LEAVE; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84856093637     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker404     Document Type: Article

References (13)

1. Sieper J, Braun J, Rudwaleit M et al. Ankylosing spondylitis: an overview. Ann Rheum Dis 2002;61:iii8-18.
2. Reed MR, Taylor AL. Tumour necrosis factor inhibitors in ankylosing spondylitis. Intern Med J 2008;38:781-9.
3. Boonen A, Brinkhuizen T, Landewe R et al. Impact of ankylosing spondylitis on sick leave, presenteeism and unpaid productivity and estimation of the societal cost. Ann Rheum Dis 2010;69:1123-8.
4. Ward MM, Reveille JD, Learch TJ et al. Impact of ankylosing spondylitis on work and family life: comparisons with the US population. Arthritis Rheum 2008;59:497-503.
5. Boonen A, van der Linden SM. The burden of ankylosing spondylitis. J Rheumatol 2006;33:4-11.
6. Boonen A. A review of work-participation, cost-of-illness and cost-effectiveness studies in ankylosing spondylitis. Nat Clin Pract Rheumatol 2006;2:546-53.
7. Braun J, van der Horst-Bruinsma IE, Huang F et al. Clinical efficacy and safety of etanercept versus sulfasalazine in ankylosing spondylitis patients: a randomized, double-blind study (ASCEND trial). Arthritis Rheum 2011; 63:1543-51.
8. Listing J, Brandt J, Rudwaleit M et al. Impact of anti-tumour necrosis factor alpha treatment on admissions to hospital and days of sick leave in patients with ankylosing spondylitis. Ann Rheum Dis 2004;63: 1670-2.
9. Keat AC, Gaffney K, Gilber AK et al. Influence of biologic therapy on return to work in people with work disability due to ankylosing spondylitis. Rheumatology 2008;47: 481-3.
10. Pavelka K, Forejtová S, Stolfa J et al. Anti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA. Clin Exp Rheumatol 2009; 27:958-63.
11. Kristensen LE, Petersson IF, Geborek P et al. Sick leave in patients with ankylosing spondylitis before and after anti-TNF therapy: a population-based cohort study. Rheumatology 2011, Advance Access published 12 May 2011, doi:10.1093/rheumatology/ker169.
12. Barkham N, Coates LC, Keen H et al. Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis. Ann Rheum Dis 2010;69:1926-8.
13. Ara RM, Packham JC, Haywood KL. The direct healthcare costs associated with ankylosing spondylitis patients attending a UK secondary care rheumatology unit. Rheumatology 2008;47:68-71.